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Cutaneous manifestations of intestinal diseases are increasingly reported both in the adult and in the children, and this association
cannot longer be considered a simple random. Besides the well-known association between celiac disease (CD) and dermatitis
herpetiformis (DH), considered as the cutaneous manifestation of gluten-dependent enteropathy, is more frequently reported
also the association with other mucocutaneous diseases. Among these there are both autoimmune, allergic, and inﬂammatory
diseases, but also a more heterogeneous group called miscellaneous. The knowledge about pathogenic, epidemiological, clinical,
and diagnostic aspects of CD is increasing in recent years as well as those about DH, but some aspects still remain to be deﬁned,
in particular the possible pathogenetic mechanisms involved in the association between both CD and DH and CD and other
immunological skin diseases. The aim of this paper is to describe the skin diseases frequently associated with CD, distinguishing
them from those which have a relationship probably just coincidental.
1.Introduction
In recent years, the knowledge about pathogenic, epidemio-
logical, clinical, and diagnostic aspects of celiac disease (CD)
has rapidly increased.
CD,alsoknownasceliacsprueorgluten-sensitiveentero-
pathy, can be deﬁned as a permanent intolerance to wheat
gliadins and other cereal prolamins in the small bowel
mucosa in genetically susceptible individuals. The main
expression of the disorder consists in characteristic, though
not speciﬁc, small intestine lesions that impair nutrient
absorption and improve upon withdrawal of the responsible
cereals. Nevertheless, the clinical presentation of the disease
canoftenbemisleadingashighlyvariablefromonepatientto
another, leading to frequent delays in diagnosis [1], thus it is
important to take into account both the distinction between
classical (typical), subclinical (atypical or mono-symptoma-
tic), silent (asymptomatic) and potential/latent CD [2]a s
well as the extraintestinal manifestations of the disease
and/or the diﬀerent associated disorders aﬀecting diﬀerent
organs and systems recently classiﬁed as autoimmune,
idiopathic, chromosomal, and miscellaneous. Among them
there are many mucocutaneous diseases. In 2006, Humbert
et al. proposed to classify skin diseases associated with CD
in those improved by gluten-free diet and those occasionally
associated with CD, dividing them into four categories:
autoimmune, allergic, inﬂammatory, and miscellaneous [3]
(Table 1).
In the present paper, the main features of the skin and
oral diseases with a proven association with CD and those
that improve after a gluten free-diet were described. More-
over, other skin conditions sporadically associated with CD
as well as dermatologic manifestation secondary to nutri-
tionaldeﬁcienciesduetotheenteropathywerebrieﬂyreport-
ed.
2. DermatitisHerpetiformis
The most important skin disease closely associated with CD
is dermatitis herpetiformis (DH), currently considered as2 Gastroenterology Research and Practice
Table 1: Skin diseases associated with CD (adapted from Humbert et al. [3].
Proved
association
Improvement in skin disease by gluten free-diet
or/and presence of serologic markers in several data
Fortuitous association
(sporadic cases reports)
Autoimmune
diseases
Dermatitis
herpetiformis
Alopecia areata
Cutaneous vasculitis
IgA linear dermatosis
Dermatomyositis
Vitiligo
Lupus erythematosus
Lichen sclerosous
Allergic diseases Urticaria
Atopic dermatitis Prurigo nodularis
Inﬂammatory
diseases Psoriasis
Palmoplantar pustolosis
Pytiriasis rubra pilaris
Erythroderma
Miscellaneous
diseases
Oral mucosa
Chronic ulcerative stomatitis
Necrolytic migratory erythema
Cutaneous amyloidosis
Annular erythema
Partial lipodystrophy
Generalized acquired cutis laxa
Ichthyosis
Transverse leukonychia
the cutaneous manifestation of gluten-dependent enteropa-
thy. DH, initially described by Louis Duhring in 1983 [4], is
considered an autoimmune skin disease with an estimated
prevalence range from 1,2 to 39,2 per 100.000 and an incid-
ence range of 0,4 to 2,6 per 100.000 per year with geograph-
ical variability. Males have a higher prevalence of DH [5]. In
fact,mostpopulation-basedstudiestodatehavefoundmale-
to-female ratios ranging from 1,5:1 to 2:1 [6]. Interestingly,
the opposite has been shown about gender prevalence of CD,
with female-to-male ratios ranging from 2:1 to 4:1. The
time of onset of the disease is variable. Cases of childhood
DH are currently more often reported than in the past, but
the average age at presentation varies from 30 to 40 years
old [7, 8]. A recent epidemiological study conducted by
Salmi et al. [9] in Finland reported some interesting results
about the increasingly rarity of DH. Although the rates of
incidence and prevalence of DH, in the Finnish population
in the thirty years between 1980 and 2009, were higher
than those of previous studies conducted elsewhere, in the
course of time there was a downward trend especially in the
90s. In particular, the estimated prevalence rate was 75,3
per 100000, while annual incidence rates were respectively
5,2 per 100000 in 1980–1989, 2,9 per 100000 in 1990–1999
and 2,7 per 100000 in 2000–2009, with a decrease in incid-
ence rate between the ﬁrst and second 10-year period that
was statistically signiﬁcant. In the study of Salmi et al. [9]
emerged a ratio between DH and CD of 1:8, that result-
edlower than 1:5 showed in previousstudies [10].Theoreti-
cally, the risk of a celiac patient to develop DH remains high,
but, being the diagnosis of the enteropathy and therefore the
adoption of gluten-free diet ever earlier, the risk of DH is
drastically reduced [9] as postulated also by Fry [11].
DH lesions show a typical polymorphism consisting of
erythema, urticarial plaques, papules, grouped vesicles and
blisters associated with intense itch and therefore followed
by erosions, excoriations, and hyperpigmentation (Figure 1).
In addition to the morphology, also the symmetrical
distribution of the lesions on the extensor surfaces of the
upper and lower extremities, elbows, knees, scalp, nuchal
area, and buttocks is considered a hallmark of the disease. At
times face and groins may be involved. DH is rarely observed
in darker-skinned individuals [12, 13]; however, there were
no signiﬁcant clinical diﬀerences compared to those North
European.
Since 1971, sporadic cases of DH presenting as palmo-
plantar purpura were reported. This uncommon skin mani-
festation is usually observed in the children, but a number of
adult cases have been described. [14–16]
Since clinical presentation of DH is often atypical, espe-
cially in early and later stages in which prevailing scratching
lesions, this diagnosis may not come to mind. DH must be
diﬀerentiated from atopic dermatitis, scabies, papular urti-
caria, and impetigo in children, whereas eczema, other auto-
immune blistering diseases (especially linear IgA bullous dis-
ease and bullous pemphigoid), prurigo nodularis, urticaria,
and erythema multiforme should be considered in adults
[17].
The diagnosis of DH is based on physical examination,
histopathology, immunoﬂuorescence studies, and serologic
testing.
Routine histopathology of lesional skin of DH, that
should ideally contain an intact vesicle or should be taken in
the vicinity of early blisters [18], can be evocative, but not
diagnostic, and nonspeciﬁc. Furthermore, the lesions pre-
sent characteristic histopathological changes, in fact the
initial inﬂammatory event is variable edema in the papillary
dermis with discrete subepidermal vacuolar alteration and
neutrophils along the dermal-epidermal junction. As the
lesion develops, neutrophils, to a lesser extent eosinophils,
and ﬁbrin accumulate within the dermal papillae and form
microabscesses. These become conﬂuent resulting in a sub-
epidermal blister. In early stages of the disease, the inﬂam-
matory inﬁltrate contains mostly neutrophils, but in later
stages, variable numbers of eosinophils can be present [19].Gastroenterology Research and Practice 3
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Figure 1: Erythematous, popular, and vesiculosus lesions in a patient with DH.
However,aprevalentlymphocyticinﬁltratewasalsoreported
by Warren et al. [20] probably corresponding to a later stage
of the disease.
However, direct immunoﬂuorescence (DIF) on perile-
sional skin should be considered the gold standard for the
diagnosis [21, 22].
In particular, two diﬀerent patterns of DIF are possible:
(a) granular deposits in the dermal papillae and (b) granular
deposits along the basement membrane. Sometimes, a
combination of both patterns, consisting in granular IgA
deposition along the basement membrane with accentuation
at the tips of the dermal papillae, may be present [23, 24].
Recently Ko et al. suggested the existence of a third diﬀerent
pattern of IgA deposition at DIF, the ﬁbrillar pattern, that
may be related to a clinical variant of DH [25].
Also serologic tests, and in particular IgA antitissue
transglutaminase antibodies (anti-tTG) and IgA endomysial
autoantibodies (EMA), have become relatively sensitive and
speciﬁc tools for detection of gluten-sensitive diseases and
therefore of DH in subjects on a diet free. Other serologic
tests for the diagnosis of DH include the detection of
antibodies directed to epidermal TG (eTG), that is currently
considered the key autoantigen in DH, as well as antideami-
dated gliadin peptides antibodies (IgA and IgG), that are
particularly reliable in children under two years old, and
antibodies against to the covalent complex tTG-deamidated
gliadin peptides, that was coined as neoepitope [26, 27].
Currently, the diagnosis of CD in patients also aﬀected by
DH not requires further investigation because skin disease is
suﬃcient for diagnosis of CD [28].
To date, the ﬁrst-line therapy of DH, as well as CD, is
gluten-free diet, that should not be considered as a mere
symptomaticapproachandthereforecontinuewithoutinter-
ruption even after clinical remission [29]. Generally, several
months are necessary to obtain the control of the skin dis-
ease.Forthisreason,othertreatmentmaybeusedassympto-
matic agents such as dapsone, sulfasalazine and sulphame-
thoxypyridazine, topical potent or very-potent corticoster-
oids, and antihistamines.
Since 1950, when the ﬁrst report on successful use of
dapsone in the treatment of DH was published [30], dap-
sone became the best tolerated symptomatic pharmacologic
therapy for DH in both adults and children. In particular,
the anti-inﬂammatory properties of this drug are linked to
inhibition of neutrophil recruitment and local neutrophil-
and eosinophil-mediated tissue injury.
Dapsone represents a valid therapeutic option during the
1- to 2-year period until the GFD is eﬀective; dosages of
1/mg/kg/day can control itching and blister development.
The commonest side eﬀect of dapsone is haemolysis and4 Gastroenterology Research and Practice
Figure 2: Erythematous scaly lesions of the buttocks in a patient
aﬀected by psoriasis.
patients should be seen within 2 weeks after starting the drug
as haemolysis may be acute in some individuals [17].
Sulfasalazine and sulphamethoxypyridazine might pro-
videaneﬀectivealternativetodapsoneespeciallywhenitfails
tocontrolthediseaseorthetherapyiscomplicatedbyadverse
events [17].
3. Psoriasis
Among the inﬂammatory skin diseases improved by gluten-
free diet, psoriasis is one of the most important. Psoriasis
is a common chronic relapsing inﬂammatory disease of the
skin, which aﬀects about 2% of general population and cha-
racterized by scaling, erythema, and less commonly postula-
tion (Figure 2). Some patients have aﬀected nails and joints
(psoriatic arthritis) with an obvious decline in quality of life
[31].
Psoriasis is an immunological disease with an important
genetic predisposition linked to HLA-Cw∗0602 [32], which
is characterized by hyperproliferation of keratinocytes medi-
atedbyTcells[33].Inparticular,Th1andTh17lymphocytes
contribute to the pathogenesis of psoriasis through the
release of inﬂammatory cytokines that promote further
recruitment of immune cells, keratinocyte proliferation, and
sustained inﬂammation. The inﬂammatory environment
seems to be ampliﬁed due to the plasticity of T regulatory
cells [34], that can convert into IL-17 producing cells. More-
over genetic, experimental and therapeutic evidences have
highlighted a central role for the innate immune system in
the pathogenesis of psoriasis [35].
The pivotal role of immune system in psoriasis patho-
physiology is also conﬁrmed by the frequent association with
other immunological diseases.
The treatment of psoriasis is often diﬃcult, although CD
patientsusuallyshowanimprovementonlyadoptingtheglu-
ten-free diet, as stated above, and then suggesting patho-
genetic diﬀerences compared to nonceliac-psoriatic patients.
About the association between P and CD, we must consider
a recent cohort study developed by Ludvingsson et al. that
showed an increased risk of psoriasis both before and after
CD diagnosis. Speciﬁcally, they showed that the absolute
risk of future psoriasis in patients with CD was 135/100,000
person-years, with an excess risk of 57/100,000. The hazard
ratio (HR) for psoriasis remained around 1.7 also when they
excluded the ﬁrst year of followup. Even 5 years after CD
diagnosis we did detect more than 60% increased risk for
psoriasis in patients with CD [36]. Several studies suggest-
ed a correlation between psoriasis and CD [37, 38], showing
an improvement in psoriatic skin lesions after 3–6 months of
gluten-free diet without other pharmacological approaches
[39, 40]. However, at present the relationship between CD
and psoriasis remains controversial since there are few data
available in the literature, and this association is consider-
edtobecoincidentalbysomeauthors[41–43].Toourknow-
ledge, no epidemiological studies are currently available
demonstrating the prevalence of psoriasis in celiac patients.
In 2001, Ojetti et al. showed a prevalence of CD of 4,34%
in 92 psoriatic patients [37], while Zamani et al. denied the
increase prevalence of CD in Iranian psoriatic patients with
respect to general population as the estimated prevalence
was 0,3% [44]. However, in 2009, a new study by Birkenfeld
et al. conﬁrmed the increased prevalence of CD also in
Asian population aﬀected by psoriasis with a prevalence rate
varying from 0 to 29% against 0–11% of controls [45]. Fin-
ally, the most recent study of Montesu et al. showed a celiac
prevalence of 2% in patients with psoriasis, conﬁrming an
increase than in the general population [46].
The mechanisms implicated in the possible association
between CD and psoriasis, and consequently the eﬀect of
gluten-free diet on psoriatic skin lesions are currently not
known. Three diﬀerent hypotheses have been proposed:
(1) abnormal small intestinal permeability, frequently
present both in psoriatic [47] and in CD patients
[48], could be a triggering factor between CD and
psoriasis;
(2) T cells play an important role in the pathogenesis of
both psoriasis and CD. An increased number of T
CD4+ cells in the blood, in the dermis, and in the
epidermis of psoriatic patients have been document-
ed [49]. In CD patients, gliadin induces a sensitiza-
tion of T CD4+ cells [50], and this may play a role in
the pathogenesis of psoriatic skin lesions [51];
(3) psoriatic lesions in CD patients could be related to
vitamin D deﬁciency, which is present both in CD
[52] and in psoriasis [53, 54].
Moreover, recent observations of Troncone and Jabri [55].
suggested that psoriasis could be considered as a part of
gluten sensitivity at least in a subgroup of patients. In those
patients, the site of immunization against gluten may be
extraintestinal and or TG is probably not the main target
antigen,since16%ofpatientswithpsoriasishavebeenfound
to present high levels of IgA and or IgG antibodies to gliadin
in the absence of anti-TG antibodies, showing a signiﬁcant
reduction when they were put on a gluten-free diet [56].
4.AlopeciaAreata
Alopecia areata (AA) is an autoimmune disease that presents
as nonscarring hair loss, with a frequency ranging from 0.7%Gastroenterology Research and Practice 5
Figure 3: AA of scalp, beard, eyelashes, and eyebrows in patient
aﬀected by CD.
to 3.8% of their patients [57, 58]. Although some studies
showed a signiﬁcant male preponderance in adult age group,
others demonstrated the opposite, indicating that AA likely
aﬀects males and females equally, as our personal clinical
experience may suggest [59–61]. The disease prevalence
peaksbetweenthesecondandfourthdecadesoflife[62],and
pediatricreportsarecommonaccountingfor20%ofallcases
[63]( Figure 3).
For the ﬁrst time, in 1995 Corazza et al. [64]d e s c r i b e d
the association between AA and CD in 3 patients and devel-
oped a prospective screening program to ascertain whether
this novel association could be real or coincidental. The esti-
mated prevalence rate of CD in patients with AA was 1 in 85
[64],andthereforeCDwasincludedamongtheautoimmune
diseases that may be associated with AA, in particular among
those aﬀecting the intestinal wall together with ulcerative
colitis. By contrast, in 2008 Neuhausen et al. [65] considered
the co-occurrence of CD and other autoimmune diseases
both in celiac and their ﬁrst-degree relatives in the North
Americanpopulationwithoutﬁndinganincreasedincidence
of AA diﬀerent from other autoimmune diseases such as
insulin-dependent diabetes mellitus, juvenile rheumatoid
arthritis/juvenile idiopathic arthritis, and hypothyroidism.
Our review of the literature showed that the reported cases
of association between these two conditions are few but,
being often more severe variant of AA, in particular alopecia
universalis, also as only clinical presentation of CD, an active
searchforCDusingserologicalscreeningtestsshouldbeper-
formed to diagnose the numerous cases of subclinical CD
and avoid uncomfortable gastrointestinal and extraintestinal
manifestations.
Although remission and recurrence may be observed
during the clinical course of AA, many patients on gluten-
free diet showed complete regrowth of scalp and other body
hair and no further recurrence of AA at followup. The
positive eﬀects of gluten-free diet on the pattern of autoim-
mune conditions, such as AA, associated with CD have been
attributed to a normalization of the immune response [66].
Figure 4: Pink-to-red edematous lesions, that have pale centers
localized on the back of a patient aﬀected by urticaria.
5.ChronicUrticaria
Urticaria is a common disorder, occurring in 15–25% of
individuals at some point in life [67]. It is characterized by
recurrent, itchy, pink-to-red edematous lesions that often
have pale centers. The lesions can range in size from a few
millimeters to several centimeters in diameter, and are often
transient, lasting for less than 48 hours [68–71]( Figure 4).
Approximately40%ofpatientswithurticariaalsoexperience
angioedema [68].
Urticaria is generally classiﬁed as acute (AU) or chronic
(CU) depending on the duration of symptoms. AU refers to
lesions that occur for less than 6 weeks, while CU to lesions
that occur for more than 6 weeks; it is usually assumed that
the lesions are present most days of the week [72].Most cases
of urticaria are acute; however, approximately 30% go on
to become chronic. AU and CU are also distinguished by
the prognosis, as AU can generally be easily managed and
is associated with a good prognosis, while CU is often asso-
ciated with signiﬁcant morbidity and a diminished quality of
life [70].
In 1987, Hautekeete et al. ﬁrst described the association
between CD and CU [71], although this is a matter still
under debate [73]. Indeed, the relationship between the two
d i s e a s e si sn o tc l e a r[ 74], but it can be speculated that auto-
immunity induced by gliadin or by other unknown antigens
may link CU and CD. The increased permeability of intesti-
nal mucosa allows the passage of antigens that are respon-
sible for CU pathogenesis by the formation of circulating
immunocomplexes[75].BothCDandurticariaareimmune-
mediated disorders, but they have a diﬀerent pathogenesis.
Infact,whileCDisaTh1-mediatedautoimmuneresponseto
gluten,urticariacouldbesupportedbydiﬀerentmechanisms
that range from Th2-driven response to allergens to Th1
autoimmunity [76]. In particular, autoimmune urticaria is
related to autoantibodies against the α subunit of the high-
aﬃnity IgE receptor FcεR1 or against the α subunit of IgE.
These antibodies are able to induce the mast cells degranula-
tion and the consequent formation of anaphylatoxin [76].
However, the only epidemiologic study assessing the pre-
valence of CD in a population of adult idiopathic CU (ICU)
patientswaspublishedin2005byGabriellietal.[73]without
demonstrating an increased risk of CD in patients with ICU.6 Gastroenterology Research and Practice
These data, obtained on a population of 80 subjects aﬀected
by ICU and 264 healthy controls, were not conﬁrmed by
larger and more detailed epidemiological studies and are in
contrast not only with several case reports, but also with
the results of a recent study by Conﬁno-Cohen et al. [77].
This study considered all autoimmune diseases potentially
associated to CU ﬁnding thyroid diseases the most common
one and also CD the more frequent among female aﬀected
by CU. In particular, when comparing women with CU with
womeninthecontrolgroup,theoddsofhavingCDwas57,8,
and in most cases the diagnosis of CD followed that of CU,
emphasizing that a screening through the determination of
the serological markers of CD in patients suﬀering from CU
may improve the prognosis of these patients.
Furthermore, even if no meta-analysis is still available,
in some cases of CU the adoption of a gluten-free diet has
proven eﬀective in controlling the skin lesions [74, 76], fur-
ther conﬁrming that CU may be a cutaneous manifestations
of CD and not only a chance association.
6. Hereditary Angioneurotic Edema
Hereditaryangioneuroticedema(HANE)isarareautosomal
dominant genetic disorder resulting from an inherited deﬁ-
ciency or dysfunction of the C1 inhibitor, a plasma protease
inhibitor that regulates several proinﬂammatory pathways.
Three phenotypic variants of HANE have been deﬁned: type
I HANE, that is characterized by a quantitative and func-
tional deﬁciency of C1 inhibitor (80–85% of cases); type II
HANE, which is associated with normal C1 inhibitor levels,
but low function (15–20% of cases); type III HANE, that
includes rare cases, usually female, in which there are no
alterations of quantity and functions of C1 inhibitor and
the genetic defect in most cases involves the expression of
factor XII (Hageman) resulting in increased production of
bradykinin [78, 79].
Clinically, HANE is characterized by recurrent episodes
of angioedema, without U or pruritus, which most often
aﬀect the skin or mucosal tissues of the gastrointestinal and
upper respiratory tracts. Although generally benign condi-
tions, laryngeal involvement can rapidly lead to fatal asphyx-
iation if left untreated. HANE usually presents in late child-
hood or adolescence in otherwise healthy subjects, and a
familial history is present in approximately 75% of cases.
These epidemiological features are useful for the diﬀeren-
tial diagnosis with acquired angioneurotic edema (AANE),
which is not associated with a family history, and usually
develops in older patients (fourth decade of life) with an
underlyinglymphoproliferativeorautoimmunedisease[80].
Cases of HANE associated with ulcerative colitis and
Crohn’s disease have been reported by Brickman et al. in
1986 [81] and after by Farkas et al. in 1999. In 2002,
Farkas et al. ﬁrst described the simultaneous occurrence of
HANE and CD in a 14-year-old white male, which adopted
gluten-free diet three years before following the diagnosis of
CD, but represented similar clinical manifestations that was
hardly ranked as HANE [82]. The knowledge and the ability
to diagnose HANE is important not only for its frequent
association with CD, particularly because of their confusion
as Farkas et al. [83] reiterated in 2011. The aim of their study
was to assess the prevalence of immunoregulatory disorders
within the patient population aﬀected by HANE, including
CD, and contrary to other, CD was actually more common,
withaprevalenceof3,1%inpatientswithHANEagainstthat
in healthy controls of 0,64%. Furthermore, according to the
authors, similarities between the symptoms of HANE, and
CD may cause diﬃculties in diﬀerential diagnosis, as well as
in choosing the appropriate therapy, suggesting the screen-
ing for CD in HANE patients in whom abdominal attacks
or neurological symptoms persist despite adequate manage-
ment.
The classic activation pathway of the complement system
plays a potential role in the immune regulation of both dis-
orders, since C1 inhibitor is deﬁcient in HANE and gluten is
considered potent activator of the alternative pathway of the
complement in CD [84]. Nevertheless, there might also be a
genetically determined etiology of both diseases [85]. Com-
plement testing is justiﬁed whenever the gastrointestinal
symptoms of CD persist despite restoration of damaged
mucous. Conversely, HANE unresponsive to adequate pro-
phylaxis should prompt for complete gastrointestinal group
tests [86].
In the literature, there are no data available about the
eﬀectiveness of the gluten-free diet.
7.CutaneousVasculitis
In the literature, there are sporadic reports about the asso-
ciation between cutaneous vasculitis (CV) and CD [86–88].
Vasculitis (V) is deﬁned as inﬂammation directed at
vessels, which compromises or destroys the vessel wall lead-
ing to haemorrhagic and/or ischaemic events. The skin is
the most common involved organ, and clinical manifesta-
tions include U, inﬁltrative erythema, petechiae, purpura,
purpuricpapules,haemorrhagicvesiclesandbullae,nodules,
livedo racemosa, deep (punched out) ulcers, and digital gan-
grene. These varied morphologies are a direct reﬂection of
size of the vessels and extent of the vascular bed aﬀected,
ranging from a V aﬀecting few superﬁcial, small vessels in
petechialeruptionstoextensivepan-dermalsmall-vesselVin
haemorrhagic bullae to muscular vessel V in lower extremity
nodules with livedo racemosa [89]. Aetiologically, vasculitis
can be separated into primary V (idiopathic, including
cutaneous leukocytoclastic angiitis, Wegener’s granulomato-
sis, Churg-Strauss syndrome, and microscopic polyangiitis),
secondary V (a manifestation of connective tissue diseases,
infection, adverse drug eruption, or a paraneoplastic phe-
nomenon), or incidental V (a histological ﬁnding that is the
consequence of another pathological process such as trau-
matic ulceration or diﬀuse neutrophilic inﬁltrates) [90].
Some items may help to explain how so many diﬀerent
diseases can coexist, in fact leukocytoclastic V is often
due to immunocomplex deposition on the vessel wall, and
the antigen may be either exogenous or endogenous [91].
Therefore, increased intestinal permeability being present in
CD, antigens can penetrate and form immunocomplexes,
that can circulate because of the impaired phagocytic
functionofreticularendotheliumsystemandbedepositedinGastroenterology Research and Practice 7
Table 2: Dermatological manifestation secondary to nutritional deﬁciencies.
Zinc deﬁciency Crusty-erythematous-squamous dermatitis localized to perioriﬁcial regions, genitals and ﬂexures,
associated with diﬀuse alopecia, stomatitis, balanitis, vulvar, and proctitis
Iron deﬁciency Atrophy and dryness, itching, hair loss, atrophic glossitis, angular stomatitis, and koilonychia
Vitamin A deﬁciency Pytiriasis rubra pilaris-like
Vitamin B12 and folic acid deﬁciency Angular stomatitis, glossitis, and oral mucosa ulcers, hyperpigmentation
V i t a m i nP Pd e ﬁ c i e n c y P e l l a g r a
the skin [90]. Alternatively, an autoimmune sensitization
may result because of the release of endogenous antigens
from damaged small bowel mucosa [92].
Treatment of leukocytoclastic V is often diﬃcult; how-
ever, the use of corticosteroids and mostly the adoption of
gluten-free diet in patients with CD has proved of great help
as reported also by Marsh and Stewart [90].
8.AtopicDermatitis
Atopic dermatitis (AD) is a very common inﬂammatory skin
disease in childhood, that has a large impact on the quality
of life both of children and their families. In developed coun-
tries, AD is aﬀecting 15–20% of the children [93, 94], and its
cumulative incidence at the age of 6 based on the criteria of
Haniﬁn and Rajka, determined in a recent population-based
prospective birth cohort study in Denmark of 562 children,
was 22.8% [95]. AD usually starts within the ﬁrst 6 months
of life. Remission during life occurs before the age of 15 years
in 60–70% of cases, although some will relapse later. Most
of the children have a family history of atopic diseases, and
a high percentage of the children with AD are sensitized to
food- and/or aero-allergens [96] .T h e r ei sal a r g ev a r i a b i l i t y
in the severity of the disease: most children have mild disease
(70–84%) and are treated by general practitioners [97–99].
However, young age at onset (ﬁrst year of life), coexistent
respiratory allergy and urban living may be considered as
factors of disease severity [100].
Genetic factors are thought to be involved in the devel-
opment of AD involving several susceptibility loci.
The clinical manifestations of AD vary with age. It is
often diﬃcult to diﬀerentiate AD from other skin conditions
such as scabies, contact dermatitis, seborrheic dermatitis,
andalsotothosethatwehavealreadydescribed amongthose
more frequently associated with CD, such as DH and psori-
asis [101].
As already mentioned above, CD is considered to arise
from an inappropriate T-cell-mediated immune response
against ingested gluten in genetically predisposed subjects
[102] and therefore diﬀerent from allergic, IgE-mediated
reactions, in which the Th2-type lymphocytes are mostly
involved [103]. Thus, one would hypothesize that Th1- and
Th2-type immunity are present in a distinct patient popu-
lation, but this is still a matter of controversy [101, 104]. In
fact, some reports have suggested that allergy manifestations
are more frequent in patients with CD [105], and asthma
incidence is increased in celiac disease diagnosed in child-
hood [106]. Atopic disorders were more frequently found in
children [107] and adult patients with CD and their relatives
than in normal control subjects [108, 109]. Zauli et al. ﬁrst
showed that CD prevalence in Italian population of atopic
patients was 1%, signiﬁcantly higher than in general popu-
lation [110]. On the contrary, one single case control study
in children with CD denies the link between CD and allergy
[111].However,in2004Ciaccietal.consideredbothpatients
with and without malabsorption and showed that AD is
about 3 times more frequent in patients with CD and 2 times
morefrequentintheirrelativesthanincontrols[112].Unfor-
tunately no data are available about eﬃcacy of gluten-free
dietinatopicpatientswithCD,becausefollowupinthestudy
conducted by Ciacci et al. was limited to 1 year and did not
abate allergic manifestations, even if it cannot be excluded
that a longer period of diet may have some eﬀects [112].
9.Other CD-AssociatedSkinConditions
As reported by Humbert et al. in 2006 [3], in addition to
skin diseases with proven association with CD and those
improved by gluten-free diet and/or with positivity of celiac
serological markers, there are also fortuitous associations
with other skin conditions. After a detailed review of the
literature, we selected all the reported associations between
CD and skin conditions. Although in none of these cases has
been eﬀectively demonstrated a pathogenetic link between
the diseases, some of these associations are more common.
Particularly lupus erythematosus [113], dermatomyositis
[114], vitiligo [115], Behc ¸et disease [116], linear IgA bullous
dermatosis [117], and also both skin and mucosal manifest-
ations of lichen [118, 119] are the most frequently reported,
while prurigo nodularis [120], erythema nodosum [121],
necrolytic migratory erythema [122], porphyria [123], cuta-
neous amyloidosis [124], pityriasis rubra pilaris [125], ery-
throderma [126], partial lipodystrophy [127], generalized
acquiredcutislaxa[128],ichthyosis[129],atypicalmolesyn-
drome, and congenital giant nevus [130] result very rare.
In addition to those listed above, there are also dermato-
logical manifestations secondary to a deﬁciency of absorp-
tion of various nutrient in the intestine. The ﬁrst and only
case of pellagra associated with CD was reported in 1999 by
Schattner [131], but CD patients may also present nonspe-
ciﬁc dermatological disorders, that only a specialist can be
traced to a speciﬁc vitamin or oligoelement. Therefore, in
Table 2, we reported the main dermatological manifestations
related to speciﬁc nutritional deﬁciencies, that a CD patient
can develop during the course of the disease.
Finally, also oral cavity may be involved in course of
CD by both dental disorders or oral mucosa manifesta-
tions. Recently, Rashid M et al. described oral and dental8 Gastroenterology Research and Practice
manifestations of CD, consisting in enamel defects, delayed
eruption, recurrent aphthous ulcers, cheilitis, and atrophic
glossitis and stressed that “the diagnosis of celiac disease can
s o m e t i m e sb em a d ef r o mas m i l e ”[ 132].
10. Conclusion
Despite the knowledge about pathogenic, epidemiological,
clinical and diagnostic aspects of CD is rapidly increased in
the recent years, the possible mechanisms involved in the
association with other diseases and in particular with the
dermatological ones remain still unclear. Several hypotheses
havebeenproposeddependingonthetypeoftheassociation,
but the most probable may involve both a genetically con-
ditioned lack of mechanisms for the maintenance of immu-
nological tolerance, that consequently predisposes to auto-
immunity and an abnormal small intestinal permeability,
which may allow the crossing of endogenous or exogenous
antigens and may provoke the immunological response, vas-
cular alterations and, lastly, vitamin and aminoacid deﬁ-
ciency secondary to malabsorption in patients with CD.
Besides the importance of the diagnosis of DH, that is
virtually always associated to CD and can be considered
a speciﬁc marker of the disease, even the identiﬁcation of
the other dermatological conditions associated with gluten-
sensitive enteropathy could be signiﬁcant, highlighting the
importance of a close collaboration between gastroenterolo-
gists and dermatologists. In fact, many skin diseases reported
inthispaperareactuallymorecommonintheceliacsorshow
atypical clinical presentation often associated with resistance
to standard therapies in those patients. As a consequence, we
suggest the screening for CD in patients aﬀected by psoriasis,
AA, CU, HANE, and AD, especially in cases resistant to ﬁrst-
line therapies.
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